Houte Hans Van Sells 2,811 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Friday, November 1st, Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.28, for a total transaction of $86,096.88.

Nurix Therapeutics Stock Up 1.8 %

Shares of Nurix Therapeutics stock traded up $0.36 during trading on Thursday, reaching $20.01. The company’s stock had a trading volume of 695,140 shares, compared to its average volume of 662,076. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -6.88 and a beta of 2.14. The firm’s 50-day moving average is $20.14 and its two-hundred day moving average is $22.40. Nurix Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on NRIX shares. Royal Bank of Canada boosted their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday. HC Wainwright raised their price objective on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. Needham & Company LLC decreased their target price on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday. Stephens reissued an “overweight” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Finally, UBS Group initiated coverage on shares of Nurix Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.71.

Institutional Trading of Nurix Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. purchased a new position in shares of Nurix Therapeutics during the third quarter valued at approximately $12,432,000. FMR LLC boosted its holdings in Nurix Therapeutics by 675.9% in the third quarter. FMR LLC now owns 586,902 shares of the company’s stock valued at $13,188,000 after acquiring an additional 511,256 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in Nurix Therapeutics during the 3rd quarter valued at $7,879,000. Patient Square Capital LP bought a new position in Nurix Therapeutics in the 3rd quarter worth $7,320,000. Finally, Wellington Management Group LLP boosted its stake in shares of Nurix Therapeutics by 8.8% during the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company’s stock valued at $78,243,000 after purchasing an additional 280,240 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.